180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Up 29.3% in February

180 Life Sciences Corp. (NASDAQ:ATNF) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 33,500 shares, an increase of 29.3% from the February 13th total of 25,900 shares. Currently, 2.4% of the shares of the company are short sold. Based on an average daily trading volume, of 410,200 shares, the days-to-cover ratio is currently 0.1 days.

180 Life Sciences Price Performance

NASDAQ ATNF opened at $1.07 on Tuesday. 180 Life Sciences has a 52-week low of $0.98 and a 52-week high of $17.75. The business’s 50-day moving average price is $1.36 and its 200 day moving average price is $2.04.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 180 Life Sciences in a report on Friday, March 7th.

Hedge Funds Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Rathbones Group PLC purchased a new position in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned about 2.20% of 180 Life Sciences as of its most recent SEC filing. 4.07% of the stock is currently owned by institutional investors and hedge funds.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.